Jushi (OTCMKTS:JUSHF – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Jushi and Evolus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus price target of $16.00, indicating a potential upside of 138.81%. Given Evolus’ higher probable upside, analysts plainly believe Evolus is more favorable than Jushi.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Jushi | -26.90% | N/A | -16.59% |
| Evolus | -14.39% | N/A | -19.03% |
Valuation & Earnings
This table compares Jushi and Evolus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jushi | $262.91 million | 0.39 | -$68.59 million | ($0.36) | -1.42 |
| Evolus | $297.18 million | 1.48 | -$51.64 million | ($0.67) | -10.00 |
Evolus has higher revenue and earnings than Jushi. Evolus is trading at a lower price-to-earnings ratio than Jushi, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Jushi has a beta of -0.71, meaning that its stock price is 171% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Institutional & Insider Ownership
21.7% of Jushi shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 23.1% of Jushi shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Evolus beats Jushi on 8 of the 13 factors compared between the two stocks.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Jushi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jushi and related companies with MarketBeat.com's FREE daily email newsletter.
